Roche Acquires Poseida for $1.5 Billion to Boost Off-the-Shelf CAR-T Cell Therapy Portfolio

Roche's strategic acquisition of Poseida Therapeutics for $1.5 billion marks a significant expansion of its cell therapy portfolio, particularly highlighting its commitment to advancing off-the-shelf CAR-T cell therapies[1][2]. This move allows Roche to fully capitalize on Poseida's innovative nonviral technology platform, expected to enhance the safety and efficacy of CAR-T treatments by using T stem cell memory cells and gene editing tools[2][3]. The acquisition not only strengthens Roche's position in oncology but also extends its reach into genetic medicine, thus reinforcing its long-term strategy to develop comprehensive solutions across oncology, immunology, and neurology[3].